Cardiol Therapeutics Inc.
NASDAQ:CRDLDrug Manufacturers - Specialty & Generic
-$0.01 today
- Market cap
- $114.64M
- Beta
- 0.80
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.31M
Average 0.68M
CRDL Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Cardiol Therapeutics Inc.NASDAQ: CRDL
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 19.0% from a year ago
Common stock stood at CA$213.35M at the end of Q1 FY2026, up 19.0% from a year earlier and up 5.7% from the prior quarter. Over 3 fiscal years it compounded at +22.9% a year.
Context
- Common stock amounted to 677.6% of total assets at the end of Q1 FY2026, down 27.0 pp from a year earlier.
- Common stock increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +19.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
CAD · from the balance sheet
- Latest · FY2025
- 201.87M CAD
- Year-over-year change
- +12.6%
- 4-year CAGR
- +9.0%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 201.87M | +12.6% |
| FY2024 | 2024-12-31 | 179.34M | +20.7% |
| FY2023 | 2023-12-31 | 148.52M | +36.5% |
| FY2022 | 2022-12-31 | 108.84M | -23.8% |
| FY2021 | 2021-12-31 | 142.92M | — |
Common Stock vs competitors
How CRDL compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +19.0% is the 4th highest of 10, against a peer median of +2.6%.
- Common stock amounts to 677.6% of total assets for CRDL, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | ₪675.6M ILS | +2.6% | +2.2% | 97.8% | |
| Mar 2026 | CA$213.35M CAD | +19.0% | +22.9% | 677.6% | |
| Mar 2026 | €8.68M EUR | +6.8% | +17.4% | 17.7% | |
| Mar 2026 | $672K USD | +93.1% | +103.3% | 0.9% | |
IMAImageneBio Inc | Mar 2026 | $11K USD | -77.1% | -32.6% | 0.0% |
| Mar 2026 | $10K USD | +25.0% | +12.6% | 0.0% | |
| Dec 2025 | $10K USD | +0.0% | +0.0% | 0.0% | |
| Mar 2026 | $8K USD | +33.3% | +17.0% | 0.0% | |
KLRSKalaris Therapeutics Inc | Mar 2026 | $2K USD | +0.0% | — | 0.0% |
| Mar 2026 | $1K USD | -88.9% | -41.5% | 0.0% | |
| Peer median (excluding CRDL) | — | +2.6% | +7.4% | 0.0% | |
Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 83.9M | 43.83M | 34.93M | 30.58M | 21.42M |
| Short-term Investments | 0 | 45.65K | 0 | 0 | 0 |
| Net Receivables | 65.74K | 354.24K | 279.87K | 361.62K | 226.2K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 341.39K | 0 | 0 | 0 | 0 |
| Total Current Assets | 87.14M | 45.32M | 36.15M | 31.67M | 23.5M |
| Property, Plant & Equipment (Net) | 356.49K | 218.17K | 337.06K | 195.59K | 118.09K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 379.25K | 217.48K | 210.36K | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 735.74K | 435.64K | 547.42K | 195.59K | 118.09K |
| Total Assets | 87.88M | 45.76M | 36.7M | 31.86M | 23.62M |
| Account Payables | 4.14M | 6.16M | 7.62M | 6.98M | 0 |
| Short-term Debt | 0 | 37.21K | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.66M | 1.04M | 238.18K | 0 | 5.62M |
| Total Current Liabilities | 11.57M | 7.23M | 8.3M | 7.01M | 5.66M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | (0) | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 72.87K | 16.54K | 158.53K | 125.52K | 87.18K |
| Total Liabilities | 11.64M | 7.25M | 8.45M | 7.14M | 5.74M |
| Common Stock | 142.92M | 108.84M | 148.52M | 179.34M | 201.87M |
| Retained Earnings | (83.52M) | (84.43M) | (142.58M) | (179.25M) | (213.07M) |
| Accumulated OCI | 4.18M | 2.6M | 3.52M | 0 | 0 |
| Other Stockholders Equity | 829 | 0 | (666) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 76.24M | 38.51M | 28.25M | 24.73M | 17.88M |
| Total Debt | 117.58K | 53.76K | 174.34K | 158.53K | 125.52K |
| Net Debt | (83.78M) | (43.77M) | (34.76M) | (30.42M) | (21.29M) |
Cardiol Therapeutics Inc.
NASDAQ:CRDL
Intrinsic Alpha fair value
Locked
Current Price
$0.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.